Jonathan Eric Zuckerman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonathan Eric Zuckerman has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
Anthony Sisk
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
3 shared publications- Anatoly Urisman
Department of Pathology, University of California San Francisco, San Francisco, California
2 shared publications Carl E. Schulze
Division of Nephrology, Department of Medicine, University of California, Los Angeles, California
2 shared publicationsClaude Bassil
Department of Onco‐Nephrology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA
2 shared publications- Edgar V. Lerma
University of Illinois at Chicago College of Medicine, Chicago, Illinois
2 shared publications - Erik Lawrence Lum
Department of Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA
2 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- Open Access
- 30 September 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (4)
Recurrent Posttransplant Antiglomerular Basement Membrane Nephritis in Alport Syndrome With Unusual Electron-Dense Deposits and Rapid Crescentic Progression
- 30 September 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (4)
Open AccessRecurrent Posttransplant Antiglomerular Basement Membrane Nephritis in Alport Syndrome With Unusual Electron-Dense Deposits and Rapid Crescentic Progression
- Open Access
- 30 September 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (4)
Donor Derived Renal Sclerosing Peritubal Nodules in an Early Posttransplant Biopsy: A Histologic Clue to Donor Neurofibromatosis
- 30 September 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (4)
Open AccessDonor Derived Renal Sclerosing Peritubal Nodules in an Early Posttransplant Biopsy: A Histologic Clue to Donor Neurofibromatosis
- Open Access
- 14 May 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (7) , 101402
Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia
- 14 May 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (7) , 101402
Open AccessSerine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia
- Open Access
- 16 April 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (2)
Dueling Fibrils. Concurrent ALECT2 Amyloidosis and DNAJB9-Positive Fibrillary Glomerulonephritis: A Case Report
- 16 April 2026
- Published by Elsevier in Kidney International Case Reports
- Vol. 1 (2)
Open AccessDueling Fibrils. Concurrent ALECT2 Amyloidosis and DNAJB9-Positive Fibrillary Glomerulonephritis: A Case Report
- Open Access
- 1 January 2026
- Published by S. Karger AG in Glomerular Diseases
- Vol. 6 (1) , 178-183
Contactin-1-Associated Membranous Nephropathy after Multiple mRNA 1273 COVID-19 Vaccinations: A Case Report
Contactin-1-associated membranous nephropathy is a rare type of membranous nephropathy typically seen in the setting of chronic inflammatory demyelinating polyneuropathy. Here we present a case of a 79-year-old man who presented with ankle edema and was found to have 2,888 milligrams of proteinuria per 24 h and membranous nephropathy on kidney biopsy. Staining for multiple membranous antigens including phospholipase A-2 receptor, NELL-1, and EXT-2 were negative. Liquid chromatography tandem mass spectrometry was performed on glomeruli and identified contactin-1 as the target antigen. Classic secondary causes of membranous nephropathy were excluded including systemic autoimmune disease, malignancies, and medications. Interestingly, the membranous nephropathy occurred 1 month after receiving the last of five doses of mRNA COVID 1273 that occurred over a 19-month period. The patient subsequently underwent spontaneous remission without initiation of disease targeted therapy, suggesting a tentative association between the COVID-19 vaccination and the membranous nephropathy. Additionally, this patient did not have any significant neuropathies typically seen with contactin-1-associated membranous nephropathy. To our knowledge, this is the first case report demonstrating a temporal association between contactin-1-associated membranous nephropathy and vaccination against COVID-19 with mRNA 1273. Our findings in this case broaden the clinical spectrum of the rare contactin-1-associated membranous nephropathy.
- 1 January 2026
- Published by S. Karger AG in Glomerular Diseases
- Vol. 6 (1) , 178-183
Open AccessContactin-1-Associated Membranous Nephropathy after Multiple mRNA 1273 COVID-19 Vaccinations: A Case Report
Contactin-1-associated membranous nephropathy is a rare type of membranous nephropathy typically seen in the setting of chronic inflammatory demyelinating polyneuropathy. Here we present a case of a 79-year-old man who presented with ankle edema and was found to have 2,888 milligrams of proteinuria per 24 h and membranous nephropathy on kidney biopsy. Staining for multiple membranous antigens including phospholipase A-2 receptor, NELL-1, and EXT-2 were negative. Liquid chromatography tandem mass spectrometry was performed on glomeruli and identified contactin-1 as the target antigen. Classic secondary causes of membranous nephropathy were excluded including systemic autoimmune disease, malignancies, and medications. Interestingly, the membranous nephropathy occurred 1 month after receiving the last of five doses of mRNA COVID 1273 that occurred over a 19-month period. The patient subsequently underwent spontaneous remission without initiation of disease targeted therapy, suggesting a tentative association between the COVID-19 vaccination and the membranous nephropathy. Additionally, this patient did not have any significant neuropathies typically seen with contactin-1-associated membranous nephropathy. To our knowledge, this is the first case report demonstrating a temporal association between contactin-1-associated membranous nephropathy and vaccination against COVID-19 with mRNA 1273. Our findings in this case broaden the clinical spectrum of the rare contactin-1-associated membranous nephropathy.
- Open Access
- 18 December 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (3) , 363-372
Obesity-related glomerulopathy, A growing kidney burden in the obesity pandemic
Obesity can cause the progression of kidney disease through hemodynamic, structural, and metabolic changes, and predispose individuals to arterio-nephrosclerosis, diabetic nephropathy, and focal segmental glomerulosclerosis (FSGS), leading to chronic kidney disease (CKD). Obesity-Related Glomerulopathy (ORG) is defined as clinical obesity and biopsy-proven glomerulomegaly with or without the existence of FSGS. However, pathologic changes of ORG are not pathognomonic or specific. Glomerular hypertrophy, maladaptive segmental glomerulosclerosis, as well as in some cases diabetic-like changes may be seen secondary to any cause of acquired or congenital reduced nephron mass with compensatory hypertrophy as well as glomerular hypoxia. This review aims to provide a comprehensive overview of the mechanisms causing ORG and explore current diagnostic challenges and therapeutic strategies, emphasizing the role of weight management and emerging targeted therapies.
- 18 December 2025
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (3) , 363-372
Open AccessObesity-related glomerulopathy, A growing kidney burden in the obesity pandemic
Obesity can cause the progression of kidney disease through hemodynamic, structural, and metabolic changes, and predispose individuals to arterio-nephrosclerosis, diabetic nephropathy, and focal segmental glomerulosclerosis (FSGS), leading to chronic kidney disease (CKD). Obesity-Related Glomerulopathy (ORG) is defined as clinical obesity and biopsy-proven glomerulomegaly with or without the existence of FSGS. However, pathologic changes of ORG are not pathognomonic or specific. Glomerular hypertrophy, maladaptive segmental glomerulosclerosis, as well as in some cases diabetic-like changes may be seen secondary to any cause of acquired or congenital reduced nephron mass with compensatory hypertrophy as well as glomerular hypoxia. This review aims to provide a comprehensive overview of the mechanisms causing ORG and explore current diagnostic challenges and therapeutic strategies, emphasizing the role of weight management and emerging targeted therapies.
- Open Access
- 16 July 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (9) , 101071
Microscopic Tubulovenous Communications in Nonneoplastic Kidneys: A Single-Center Case Series and Review of the Literature
- 16 July 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (9) , 101071
Open AccessMicroscopic Tubulovenous Communications in Nonneoplastic Kidneys: A Single-Center Case Series and Review of the Literature
- Open Access
- 15 July 2025
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 59 (4) , 269-272
What’s new in medical renal pathology 2025: Updates on podocytopathy and immunofluorescence staining in medical kidney
Diffuse podocytopathy, including minimal change disease and primary focal segmental glomerulosclerosis, is a common cause of nephrotic syndrome in adults and children. It is increasingly recognized to be autoimmune-mediated associated with anti-nephrin and other emerging anti-slit diaphragm antibodies, and can recur in the kidney allograft. Immunofluorescence is routinely used in evaluation of kidney biopsies, and updates include those on fibrillar diseases, monoclonal staining, lupus-like staining, and use of antibody KM55 in IgA-dominant glomerulonephritis.
- 15 July 2025
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 59 (4) , 269-272
Open AccessWhat’s new in medical renal pathology 2025: Updates on podocytopathy and immunofluorescence staining in medical kidney
Diffuse podocytopathy, including minimal change disease and primary focal segmental glomerulosclerosis, is a common cause of nephrotic syndrome in adults and children. It is increasingly recognized to be autoimmune-mediated associated with anti-nephrin and other emerging anti-slit diaphragm antibodies, and can recur in the kidney allograft. Immunofluorescence is routinely used in evaluation of kidney biopsies, and updates include those on fibrillar diseases, monoclonal staining, lupus-like staining, and use of antibody KM55 in IgA-dominant glomerulonephritis.